Antibodies and Antibody-Drug Conjugate Higher Order Structures Revealed

Webinar Length: 1 hour

In this webinar you will learn:

  • How Microfluidic Modulation Spectroscopy (MMS) can be used to understand the higher order structures of therapeutic antibodies and antibody drug conjugates
  • Introduction to the AQS3™pro MMS system from RedShiftBio

Webinar Highlights

  • Characterization of mAb’s and ADC’s without the need for dilutions or concern for your formulation buffer’s excipient interferences, enabled by MMS, is critical to understand the TRUE higher order structure of your drug product at the intended therapeutic conditions.
  • Microfluidic Modulation Spectroscopy provides a reliable platform with increased sensitive and higher resolution for secondary structure analysis of biotherapeutics.
  • MMS’s Automated walk away workflow makes it applicable for screening studies much earlier in the development process.

Analyzing Protein Secondary Structure using Microfluidic Modulation Spectroscopy

Recently investigators have begun to harness new technology such as microfluidic modulation spectroscopy (MMS) to reveal protein structural changes, as a solid understanding of higher order structure and function is extremely important to the effectiveness of biotherapeutic drugs and scientists today are challenged in gathering a complete understanding with current tools.

Secondary Structure Changes Resulting from Manufacturing Processes

During the biomanufacturing process, proteins such as antibodies, often undergo conformational changes that can alter their secondary structure, leading to critical variations in their overall function. These changes have been historically difficult to detect, as traditional analytical techniques are poor at detecting small differences in protein structure. MMS however, can detect these changes with great sensitivity and accuracy without the need for dilution. Moreover, MMS offers detailed information on which structural motifs in the protein molecule are changing, providing more guidance to scientists in their efforts to develop more stable antibody molecules and formulations. Join us for this new GEN webinar where we will learn how MMS technology is making a significant impact toward understanding the structures of therapeutic antibodies and antibody drug conjugates

Speakers

Shah_Karan

Karan K. Shah

Principal Development Associate in the Analytical and Pharmaceutical Sciences department at ImmunoGen, Inc.
Papayannopoulos_photo

Ioannis Papayannopoulos

eugene-ma

Eugene Ma

Co-Founder and Chief Technology Officer, RedShiftBio

You can watch the replay by filling your details in the form.

[Webinar] Antibodies And Antibody-Drug Conjugate Higher Order Structures Revealed

  • This field is for validation purposes and should be left unchanged.

Karan K. Shah is a Principal Development Associate in the Analytical and Pharmaceutical Sciences department at ImmunoGen, Inc.

He received his M.S. in Pharmaceutical Sciences from Northeastern University and is an analytical chemist with several years of experience in the biopharmaceutical industry. His R&D experience includes formulation development as well as analysis and characterization of antibodies and antibody drug conjugates (ADCs). He has expertise in method development for characterization of antibodies and ADCs using a broad spectrum of analytical and biophysical techniques and in the application of these techniques to support CMC development.

Ioannis Papayannopoulos

Has been carrying out peptide and protein analytical work for the past several decades, using mass spectrometry, chromatography, spectroscopy, and other analytical techniques. He received his undergraduate degree in chemistry from Bowdoin College and his PhD in Organic Chemistry from the Massachusetts Institute of Technology, where he conducted research in mass spectrometry under the supervision of the late professor KlausBiemann. Over the years Dr. Papayannopoulos has alternated between academia, most recently as director of the Proteomics Facility at the Koch Institute for Integrative Cancer Research at MIT, and the biopharmaceutical industry in senior scientific and management roles at companies such as Biogen, Covance and AstraZeneca. For the past several years he has been with Celldex Therapeutics, a biopharmaceutical company in Massachusetts, working on the analysis and characterization of antibodies, antibody-drug conjugates and recombinant protein pharmaceuticals

Eugene Ma, Co-Founder and Chief Technology Officer, RedShiftBio

Eugene, CTO of RedShiftBio, is responsible for technology innovation and technical support across the full range of activities at RedShiftBio. Eugene has a BSEE from Yale University, and a MA and PhD in electrical engineering from Princeton University. He has also studied business at the Wharton School, University of Pennsylvania.